Drugs Made In America Acquisition II Corp. Reports IPO Success and Financial Losses

Drugs Made In America Acquisition II Corp. (the "Company") reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The Company, which was incorporated in August 2024, completed its Initial Public Offering (IPO) on September 26, 2025, raising gross proceeds of $500 million by selling 50 million units at $10 each. This substantial influx of capital has positioned the Company with total assets of approximately $501 million, a marked increase from $138,064 reported at the end of the previous fiscal period. The cash and investments held in the Trust Account alone amounted to $500 million, reflecting the successful execution of its IPO strategy.

In terms of operational performance, the Company reported a net loss of $46,158 for the three months ended September 30, 2025, and a total net loss of $143,558 for the nine months of the same period. This loss is primarily attributed to general and administrative costs totaling $155,513 for the quarter and $252,913 for the nine-month period. The Company generated interest income of $109,355 from its Trust Account, which partially offset these expenses. Comparatively, the net loss for the same period in 2024 was $41,684, indicating a significant increase in operational costs as the Company prepares for its business combination.

Strategically, the Company has not yet identified a target for its initial business combination but intends to focus on the pharmaceutical industry. The IPO proceeds are earmarked for this purpose, with management expressing confidence in their ability to identify and execute a successful acquisition. The Company has also established a Trust Account to safeguard the funds raised, which will only be released upon the completion of a business combination or under specific conditions related to shareholder votes.

Operationally, the Company has seen an increase in its ordinary shares outstanding, rising from 14,375,000 at the end of 2024 to 15,575,000 as of September 30, 2025. The total liabilities have also increased to $18,177,345, primarily due to accrued expenses and offering costs. The Company has a working capital of $219,011, but it faces substantial doubt regarding its ability to continue as a going concern, given the mandatory liquidation timeline if a business combination is not completed within 24 months of the IPO.

Looking ahead, the Company is focused on leveraging its capital to identify a suitable business combination while managing its operational costs. The management has indicated that they will continue to incur significant expenses in pursuit of their acquisition plans, and they are exploring potential financing options to support these efforts. The Company remains optimistic about its future prospects, although it acknowledges the inherent risks associated with early-stage companies and the current geopolitical climate that may impact market conditions.